Trial Profile
A Retrospective Study Evaluating a Modified Treat and Extend Regimen of Aflibercept in Treatment-Naive Patients with Neovascular Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 24 Aug 2017 New trial record